Sclerotherapy of oral and facial venous malformations with use of pingyangmycin and/or sodium morrhuate.
Two hundred and sixty patients with oral and facial venous malformations received intralesional injections of either pingyangmycin, sodium morrhuate, or pingyangmycin alternating with sodium morrhuate. Results were rated excellent, good, fair, or poor, depending on clinical outcome. The prevalence of an "excellent" rating in the combined sclerotherapy group (82%) was higher than that in the pingyangmycin group (71%) and the sodium morrhuate group (61%). Swelling and pain following injection were commonly associated with the use of sodium morrhuate. Sclerotherapy with pingyangmycin or sodium morrhuate is an effective and safe treatment for oral and facial venous malformations. Alternate injection of pingyangmycin and sodium morrhuate appears to be more effective for venous malformations than using sclerosant alone.
Zhao
J-H
JH
Department of Oral and Maxillofacial Surgery, College and Hospital of Stomatology, Wuhan University, Wuhan 430079, PR China.
Zhang
W-F
WF
Zhao
Y-F
YF
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D004338:Drug Combinations; D004487:Edema / Q000209:etiology; D005145:Face / Q000098:blood supply*; D005157:Facial Pain / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D008046:Lip / Q000098:blood supply; D008297:Male; D009055:Mouth / Q000098:blood supply*; D012189:Retrospective Studies; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015911:Sclerotherapy / Q000009:adverse effects; D012976:Sodium Morrhuate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014059:Tongue / Q000098:blood supply; D016896:Treatment Outcome; D014680:Veins / Q000002:abnormalities
D020533:Angiogenesis Inhibitors; D004338:Drug Combinations; D012597:Sclerosing Solutions; D001761:Bleomycin; C021771:zhengguangmycin; D012976:Sodium Morrhuate